Associated Papers
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
Lanillos J et al.
Npj Genomic Medicine, 2022
35181665 (PubMed )
Supplement: 41525_2022_283_MOESM4_ESM.xlsx › Novel_Previously_described_var.
Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content.
Shirasaka Y et al.
The Pharmacogenomics Journal, 2016
Polymorphisms of human cytochrome P450 2C9 and the functional relevance.
Zhou SF et al.
Toxicology, 2010
Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.
Limdi NA et al.
Clinical Pharmacology and Therapeutics, 2008
Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans.
Limdi N et al.
Personalized Medicine, 2007
A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapy.
Goldstein JA et al.
Blood Cells, Molecules & Diseases, 0
Select a paper to view details